Introduction

Cardiac stress testing is the most commonly used modality for diagnostic purposes in patients with known or suspected coronary artery disease (CAD). The utility of stress testing should be interpreted in light of the disease's likelihood. Patients with a low probability of disease have a high risk of false-positive results and may end up with further unnecessary invasive testing without changing patient outcomes. Those with high pretest probability have a high risk of false-negative results that can miss a critical diagnosis; therefore, these patients should proceed directly to more confirmatory testing, such as cardiac catheterization.

Stress testing is most clinically useful in intermediate-risk patients with CAD, helping further reclassify them as low- or high-risk based on the stress test result. Stress testing can also be used to obtain prognostic information, determine the patient's response to optical medical therapy, measure exercise capacity, and evaluate ischemia in patients who are already started on medical therapy for known CAD. In general exercise, stress is preferred because it provides a gauge of functional capacity, exercise tolerance, and symptom provocation.[1] Pharmacologic stress testing is an alternative modality in patients who are unable to exercise and have the following conditions:

1. Patients presenting with unstable angina.
2. History of heart failure that is not well controlled, and there is a concern for deterioration.
3. Poorly controlled blood pressure with systolic blood pressure significantly higher (>200 mmHg at rest).
4. Patients with a history of aortic stenosis, which is significantly worse on echocardiogram (aortic valve area <1.0 cm2 and mean gradient >40 mmHg), and have ongoing symptoms.[2]
5. I had a myocardial infarction last week.
6. Acute pulmonary embolism
7. Acute inflammation ofthe  pericardium or myocardium
8. Severe pulmonary hypertension

Exercise stress testing is also not very helpful in patients with an insufficient hemodynamic response to exercise due to abnormalities of the respiratory system and ongoing issues affecting muscles, bones, and peripheral vessels. Additionally, the exercise stress test is not useful when the baseline EKG is abnormal, such as left ventricular hypertrophy (LVH), left bundle branch block (LBBB), paced rhythm, Wolff-Parkinson-White (WPW) syndrome, or greater than 1 mm ST-segment depression. These patients are suitable candidates for testing involving pharmacologic agents. Pharmacologic stress testing is used in combination with imaging modalities such as radionuclide imaging and echocardiography.

Specimen Collection

Pharmacological stress testing is a highly supervised procedure conducted under the supervision of expert medical personnel, either in a clinic or a hospital. During the procedure, electrodes will be attached to the patient's chest, and vital signs will be continuously monitored. The stress agent is injected through a peripheral intravenous line, thereby increasing blood flow through the coronary vasculature and eliciting a response similar to that of exercise stress testing. Once a peak effect is attained, a small amount of radioactive material is inserted through the peripheral intravenous line. After that, a high-resolution gamma camera takes several pictures of the heart to get a better visualization of your coronary vasculature. During the resting phase, the gamma camera will acquire additional images that can be compared with the stress-induced perfusion images.

Procedures

Vasodilator agents currently approved by the Food and Drug Administration (FDA) include:

1. Adenosine
2. Dipyridamole
3. Regadenoson

Vasodilators do not stress the heart and do not cause coronary steal by temporarily increasing blood flow to non-diseased coronary vessels at the expense of diseased vessels, as visualized on nuclear imaging.[1][3]

Regadenoson is a newer vasodilator agent approved by the FDA in 2008 and is most routinely used today due to its selective action on A2A receptors and fewer side effects.

Dobutamine is an alternative drug that acts as an inotrope and can be used in pharmacological stress testing. It is not FDA-approved and is currently rarely used. However, it can be used in patients with contraindications to pharmacologic vasodilator stress agents, such as those with severe respiratory diseases, including asthma or chronic obstructive pulmonary disease (COPD), or when regadenoson is not readily available.

Indications

Indications of Pharmalogic Stress Testing include:

1. Patients who are unable to tolerate an exercise stress test due to abnormalities involving the respiratory system (severe chronic obstructive pulmonary disease (COPD)), provoked angina, hypotension during exercise, or chronotropic incompetence. These patients are suitable candidates for testing involving pharmacologic agents.[4]
2. Patients who have a baseline abnormal electrocardiogram, which includes the presence of left bundle branch block at baseline, left ventricular hypertrophy, paced rhythm, Wolf Parkinson White syndrome, and greater than 1 mm ST-segment depression. These patients can have false-positive results on an exercise stress test.
3. Symptomatic aortic stenosis.[4]

Potential Diagnosis

Medications used for stress testing diagnosis include all of the following.

Adenosine

Adenosine acts on the coronary arteries through specific activation of the A2A receptor and causes them to dilate.[5][6] There are 4 types of adenosine receptors: A1, A2A, A2B, and A3.

• Activation of the A1 receptor results in decreased atrioventricular conduction and reduces heart rate.
• Activation of A2A receptors in vascular smooth muscles in blood vessels, such as in coronary arteries, causes vasodilation
• Activation of the A2B and A3 receptors in bronchial beds can also result in bronchospasm.

Dose:

The dose of adenosine used during a pharmacologic stress test is 140 mcg/kg/min and is administered continuously for 6 minutes. The radioactive material is typically administered at 3 minutes, after which adenosine is infused for 3 more minutes. An additional method involves administering adenosine for 4 minutes via continuous infusion; its effects and outcomes are comparable to those of a 6-minute continuous infusion.[7] Adenosine generally produces a modest increase in heart rate and a modest decrease in blood pressure. The infusion results in a 3.5- to 4-fold increase in coronary blood flow over baseline. The half-life of adenosine is less than 10 seconds.[1]

Limiting caffeine intake:

Methylxanthines such as theophylline or caffeine block adenosine binding due to antagonistic action at A2A receptors and can reduce the coronary vasodilation effects of adenosine. Therefore, it is recommended to discontinue consumption of caffeine-containing medications, foods, or beverages for at least 12 hours and ideally 24 hours before adenosine stress testing.[8]

Contraindications:

1. Adenosine is contraindicated in patients with reactive airway disease with significant wheezing
2. Patients with a history of advanced conduction abnormalities, including 2nd or 3rd-degree atrioventricular block in the absence of a permanent pacemaker.
3. Patients with a history of abnormalities in the sinus node in the absence of a permanent pacemaker
4. Systolic blood pressure of less than 90 mmHg
5. Poorly controlled blood pressure with systolic blood pressure significantly higher (over 200 mmHg at rest).
6. Caffeine intake in the previous 12 hours
7. Known hypersensitivity to adenosine
8. Patients with acute coronary syndrome or unstable angina, or who experienced a myocardial infarction less than 1 week ago.

Dipyridamole

Dipyridamole was the first vasodilator used for myocardial perfusion stress testing. It is an indirect coronary artery vasodilator. It increases the tissue levels of adenosine by preventing the intracellular reuptake of adenosine by inhibiting the enzyme adenosine deaminase, prolonging its vasodilator effect, and increasing adenosine blood levels.[9][10]

Dipyridamole increases coronary blood flow by 3.8 to 7 times baseline. The alpha half-life (the initial decline following peak concentration) is approximately 30 to 45 minutes. The beta-half life (the terminal decline in plasma concentration) is approximately 10 hours. It is metabolized in the liver to a glucuronic acid conjugate and excreted in the bile.

Dipyridamole dose:

The dose of dipyridamole is 0.142 mcg/kg/min, or 0.57 mcg/kg.[9] Dipyridamole is infused over 4 min, with the radiotracer being injected 3 to 5 min after the completion of the dipyridamole infusion. Symptoms may persist longer than with other vasodilators (15-25 minutes). 

Side effects of dipyridamole:

1. The incidence of atrioventricular (AV) block with dipyridamole is less than that observed with adenosine (2%).
2. Chest pain is observed in 20% but is nonspecific and not necessarily indicative of CAD.
3. Minor side effects include headache, dizziness, nausea, hypotension, and flushing.

Contraindications:

1. Patients with bronchospastic lung disease with ongoing wheezing or a history of significant reactive airway disease should not undergo dipyridamole stress testing.
2. Uncontrolled hypertension (systolic pressure of over 200 mmHg or a diastolic pressure of over 110 mmHg)
3. A systolic blood pressure of less than 90 mmHg.
4. Known hypersensitivity to dipyridamole.
5. Caffeine intake in the previous 12 hours
6. Second- or third-degree atrioventricular block without a functioning pacemaker.

Regadenoson

Regadenoson is another direct coronary artery vasodilator, which is a selective A2A agonist. The affinity with which regadenoson binds with A2A is 10 times greater than its affinity to bind with the A1 receptor and even weaker affinity to bind with A2B and A3 receptors. Regadenoson induces maximal hyperemia rapidly and maintains it for an optimal duration, which is more practical for radionuclide myocardial perfusion imaging. Regadenoson's simple, rapid bolus administration in all patients, regardless of weight, and its short duration of hyperemic effect have greatly simplified stress testing compared with adenosine and dipyridamole. It is currently the most commonly used due to its fewer side effects and ease of administration.[11]

Regadenoson dose:

As noted earlier, regadenoson dosing is not weight-based, unlike that of other vasodilators. The standard dose of regadenoson is 0.4 mg and is available only in a prefilled 5-ml syringe. The dose is immediately followed by a saline flush. The radiotracer is administered 10 to 20 seconds later, immediately followed by another saline flush.[12] The results of the ADVANCE MPI 2 trial have shown that regadenoson is non-inferior to adenosine for the detection of reversible defects and is safe and better tolerated.[13] The half-life of regadenoson is 2 hours.

Contraindications:

1. Regadenoson is considered contraindicated for patients with second- or third-degree AV block or sick sinus syndrome.
2. Allergic response in the past to the agent
3. Hypotension with systolic blood pressure <90 mmHg.
4. Poorly controlled blood pressure with systolic blood pressure significantly higher (greater than 200 mmHg at rest)
5. Patients who received dipyridamole in the last 2 days should also avoid regadenoson stress testing.
6. Patients with acute coronary syndrome or unstable angina, or who experienced a myocardial infarction less than 1 week ago
7. Caution is advised in patients with reactive airway disease with wheezing

Reversal of vasodilator effects:

In patients who suffer from undesirable effects from pharmacologic stress testing agents, caffeine is generally given to counteract the effects. The use of caffeine to reverse the side effects is more beneficial with dipyridamole and regadenoson, due to their longer duration of action compared with adenosine. Aminophylline can be used to manage more severe side effects.

Dobutamine

Dobutamine is an inotropic agent that can be used for myocardial perfusion stress testing.[1] Dobutamine is not approved by the Food and Drug Administration for pharmacologic stress testing and is rarely used currently. Dobutamine is a beta-agonist that results in the stimulation of beta1 and beta2 receptors.[14]

Dobutamine, like exercise, increases myocardial oxygen demand and evokes ischemia if there is insufficient perfusion to the affected myocardium, which can be seen on stress echocardiography or nuclear imaging.

Beta-blockers should be withheld for 24 hours before the dobutamine stress test because of their antagonistic action.

Dobutamine dose:

Dobutamine is administered as an infusion at an initial rate of 5-10 mcg/kg/min for 3 minutes. It is increased to 20, 30, and then 40 mcg/kg/min, also for 3-min intervals, for a maximum of 12 minutes or until the target heart rate is achieved. Radiotracer is injected at peak heart rate with dobutamine infusion continuing for one minute following tracer injection. The half-life of dobutamine is 2 to 3 min. 

Indications:

1. Dobutamine is a secondary pharmacologic stress agent recommended only for patients who cannot undergo an exercise stress test and who have contraindications to pharmacologic vasodilator stress agents, such as a high degree of AV block or reactive airway disease (if regadenoson is unavailable).

Contraindications:

1. Patients with acute coronary syndrome or unstable angina, or who experienced a myocardial infarction less than 1 week ago
2. Hemodynamically significant left ventricular outflow obstruction.
3. Atrial tachyarrhythmias with an uncontrolled ventricular response
4. Hypertension (systolic blood pressure over 200 mmHg or diastolic blood pressure exceeding 110 mmHg)
5. Aortic dissection
6. Known hypersensitivity to dobutamine

Normal and Critical Findings

Pharmacological stress testing with myocardial perfusion imaging can help detect perfusion or wall-motion abnormalities that indicate either infarction (seen on both stress and rest images) or ischemia (seen on stress images only). The utility of cardiac stress testing is determined in part by pretest disease probability; false-positive results may lead to potential downstream testing and treatment. Conversely, in patients with high pretest probability of CAD, false-negative studies result in missed diagnoses. Therefore, the greatest utility is in patients with intermediate CAD probability, in whom a positive test significantly increases disease likelihood, whereas a negative test significantly decreases it. Depending on the results, further testing, such as coronary angiography, may be considered. 

Interfering Factors

Interfering factors include:

1. Caffeine and methylxanthine intake within 12 hours prior to stress testing with vasodilator stress agents.
2. Beta-blockers should be administered within the last 24 hours if the patient is undergoing dobutamine stress testing.

Complications

Pharmacological stress testing is a relatively safe procedure with minimal side effects, but patients can occasionally suffer from undesirable side effects based on the mechanism of action of the pharmacologic stress agent used. Vasodilator agents, including adenosine and dipyridamole, can produce bronchospasm and AV block. Less common with regadenoson due to its selective action. Dobutamine can cause tachyarrhythmias.

Patient Safety and Education

Caffeine is commonly offered to patients after the stress testing procedure, as it will likely reverse undesirable side effects. It is particularly helpful with regadenoson and dipyridamole, which have longer half-lives than adenosine. More serious side effects can be managed with aminophylline, an adenosine receptor antagonist.[1] Beta-blockers can be used to treat side effects or toxicity caused by dobutamine.

Clinical Significance

In the majority of patients with an inability to exercise, pharmacologic stress testing is an essential diagnostic modality and widely used for the evaluation of ischemia and coronary artery disease (CAD). It is also used to assess prognosis in individuals with known CAD.[15]

Review Questions

• Access free multiple choice questions on this topic.
• Comment on this article.

References

1.

Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. Erratum to: ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J Nucl Cardiol. 2016 Jun;23(3):640-642. [PubMed: 26961077]

2.

Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Griffin BP, Iung B, Otto CM, Pellikka PA, Quiñones M., American Society of Echocardiography. European Association of Echocardiography. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr. 2009 Jan;22(1):1-23; quiz 101-2. [PubMed: 19130998]

3.

Brink HL, Dickerson JA, Stephens JA, Pickworth KK. Comparison of the Safety of Adenosine and Regadenoson in Patients Undergoing Outpatient Cardiac Stress Testing. Pharmacotherapy. 2015 Dec;35(12):1117-23. [PubMed: 26684552]

4.

Wolk MJ, Bailey SR, Doherty JU, Douglas PS, Hendel RC, Kramer CM, Min JK, Patel MR, Rosenbaum L, Shaw LJ, Stainback RF, Allen JM., American College of Cardiology Foundation Appropriate Use Criteria Task Force. ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014 Feb 04;63(4):380-406. [PubMed: 24355759]

5.

Gulsin GS, Abdelaty AMSEK, Shetye A, Lai FY, Bajaj A, Das I, Deshpande A, Rao PPG, Khoo J, McCann GP, Arnold JR. Haemodynamic effects of pharmacologic stress with adenosine in patients with left ventricular systolic dysfunction. Int J Cardiol. 2019 Mar 01;278:157-161. [PubMed: 30528627]

6.

Shams P, Khiyani N, Zeltser R. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Dec 11, 2024. Adenosine SPECT Thallium Imaging. [PMC free article: PMC537070] [PubMed: 30725755]

7.

Bokhari S, Ficaro EP, McCallister BD. Adenosine stress protocols for myocardial perfusion imaging. J Nucl Cardiol. 2007 May-Jun;14(3):415-6. [PubMed: 17556176]

8.

Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, O'Gara PT, Carabello BA, Russell RO, Cerqueira MD, St John Sutton MG, DeMaria AN, Udelson JE, Kennedy JW, Verani MS, Williams KA, Antman EM, Smith SC, Alpert JS, Gregoratos G, Anderson JL, Hiratzka LF, Faxon DP, Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO., American College of Cardiology. American Heart Association. American Society for Nuclear Cardiology. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol. 2003 Oct 01;42(7):1318-33. [PubMed: 14522503]

9.

Lette J, Tatum JL, Fraser S, Miller DD, Waters DD, Heller G, Stanton EB, Bom HS, Leppo J, Nattel S. Safety of dipyridamole testing in 73,806 patients: the Multicenter Dipyridamole Safety Study. J Nucl Cardiol. 1995 Jan-Feb;2(1):3-17. [PubMed: 9420757]

10.

Shams P, Heston TF, Samarany S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 7, 2025. Dipyridamole Nuclear Stress Test. [PMC free article: PMC544321] [PubMed: 31335041]

11.

Moles VM, Cascino T, Saleh A, Mikhova K, Lazarus JJ, Ghannam M, Yun HJ, Konerman M, Weinberg RL, Ficaro EP, Corbett JR, McLaughlin VV, Murthy VL. Safety of regadenoson stress testing in patients with pulmonary hypertension. J Nucl Cardiol. 2018 Jun;25(3):820-827. [PubMed: 27896702]

12.

Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE., ADVANCE-MPI Trial Investigators. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging. 2008 May;1(3):307-16. [PubMed: 19356442]

13.

Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, Lieu H, Mahmarian JJ, Olmsted A, Underwood SR, Vitola J, Wang W., ADVANCE MPI Investigators. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 2007 Sep-Oct;14(5):645-58. [PubMed: 17826318]

14.

Ruffolo RR. The pharmacology of dobutamine. Am J Med Sci. 1987 Oct;294(4):244-8. [PubMed: 3310640]

15.

Gajulapalli RD, Aneja A, Rovner A. Cardiac stress testing for the diagnosis and management of coronary artery disease: a reference for the primary care physician. South Med J. 2012 Feb;105(2):93-9. [PubMed: 22267098]

Disclosure: Hassan Mehmood Lak declares no relevant financial relationships with ineligible companies.

Disclosure: Sagar Ranka declares no relevant financial relationships with ineligible companies.

Disclosure: Amandeep Goyal declares no relevant financial relationships with ineligible companies.